Online Inquiry


USA: 45-1 Ramsey Road, Shirley, NY 11967, USA
Europe: Heidenkampsweg 58, 20097 Hamburg, Germany
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356

Anti-HPV16-E6 CAR-T Preclinical in vivo Assay

Target Background

HPV16-E6 (human papillomavirus type 16) is an oncoprotein which can induce and maintain the cellular transformation by stimulating the destruction of many host cell key regulatory proteins, including tumor suppressors TP53 and TP73. It can also inhibit the cell apoptosis. As an early protein of the human papillomavirus types (HPVs), it exists in host nucleus matrix and most often associates with carcinomas of the anogenital tract, particulary cancer of the cervix (account for almost 12% of all cancers in women and represent the second most frequent gynaecological malignancy in the world). For instance, HPV16 have been reported to exist in cervical cancer cell lines and cancer biopsies, and also immortalize normal human foreskin keratinocytes in vitro. Even ~25% of oral cancers contain anogenital HPV DNA. Thus, HPV16 is one of the most important identified risk factors for widespread human cancers, and manifested as a valuable anti-HPV16-E6 CAR-T therapy target.

The human papillomavirus life cycle

The human papillomavirus life cycle
Nature Reviews Cancer 2.5 (2002): 342-350
Diagram partially created by Creative Biolabs based on data from Virology 483 (2015): 253-263

Anti-HPV16-E6 CAR-T Cell Therapy

The preclinical and clinical studies of anti-HPV16-E6 CAR-T cell therapy are so limited that only one phase 2 clinical trial (NCT02280811) has been completed to test the efficiency of genetically modified anti-HPV16-E6 T cells for HPV-associated cancers.
Creative Biolabs is dedicated to assisting researchers to initiate and develop the cutting-edge CAR-T cell therapy.

Animal Models for in vivo Study of anti-HPV16-E6 CAR-T Cell Therapy

Creative Biolabs offers researchers almost all the animal models generated from the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models for a variety of human carcinomas of the anogenital tract. In addition, Creative Biolabs also assists customers in creating clinically relevant animal models including but not limited to the above categories. You request, Creative Biolabs offers the best.

In vivo Assay Parameters and Techniques

At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical HPV16-E6 CAT-T cell therapy research.
Efficacy Test
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Toxicity Evaluation
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
Tumorigenicity study

Creative Biolabs outperforms the entire biotechnological community to back researchers with every resource for establishing the most reliable and subtle animal models in advance to help the customer achieve incredible disproportionate results and exponentially greater value. Creative Biolabs assists researchers in making the scientific history.


  1. Zur Hausen, Harald. "Papillomaviruses and cancer: from basic studies to clinical application." Nature Reviews Cancer 2.5 (2002): 342-350.
  2. Guan, Jian, et al. "Structural comparison of four different antibodies interacting with human papillomavirus 16 and mechanisms of neutralization."Virology 483 (2015): 253-263.

Online Inquiry

For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.

  • Verification code
    Click image to refresh the verification code.

Key Updates

Receive our latest news and insights.